OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: A cross sectional study

Journal of Human Genetics

Volumn 58, Issue 2, 2013, Pages 84-90

  Chen, Yu Ting ^a   Tsou, Hsiao Hui ^a   Kuo, Hsiang Wei ^a   Fang, Chiu Ping ^a   Wang, Sheng Chang ^a   Ho, Ing Kang ^a,b,c   Chang, Yao Sheng ^a   Chen, Chia Hui ^a   Hsiao, Chin Fu ^a   Wu, Hsiao Yu ^a   Lin, Keh Ming ^a   Chen, Andrew C H ^d   Tsai Wu, Jyy Jih ^e   Liu, Yu Li ^a,c,e  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Columbia University ^*  (United States)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cotinine concentration; heroin dependence; methadone; opioid receptor; OPRM1; SNP

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; COTININE; METHADONE;

ADULT; ALLELE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPRM1 GENE; PLASMA COTININE LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STATISTICAL MODEL; TAIWAN; URINALYSIS;

ADULT; COTININE; CROSS-SECTIONAL STUDIES; FEMALE; HAPLOTYPES; HUMANS; MALE; METHADONE; MIDDLE AGED; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 84875440123     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2012.139     Document Type: Article

References (67)

1. Best, D., Lehmann, P., Gossop, M., Harris, J., Noble, A. & Strang, J. Eating too little, smoking and drinking too much: wider lifestyle problems among methadone maintenance patients. Addict. Res. Theory 6, 489-498 (1998).
2. Richter, K. P., Gibson, C. A., Ahluwalia, J. S. & Schmelzle, K. H. Tobacco use and quit attempts among methadone maintenance clients. Am. J. Public Health 91, 296-299 (2001).
3. Nahvi, S., Richter, K., Li, X., Modali, L. & Arnsten, J. Cigarette smoking and interest in quitting in methadone maintenance patients. Addict. Behav 31, 2127-2134 (2006).
4. Bien, T. H. & Burge, R. Smoking and drinking: a review of the literature. Int. J. Addict. 25, 1429-1454 (1990).
5. Chait, L. D. & Griffiths, R. R. Effects of methadone on human cigarette smoking and subjective ratings. J. Pharmacol. Exp. Ther. 229, 636-640 (1984).
6. Henningfield, J. E., Clayton, R. & Pollin, W. Involvement of tobacco in alcoholism and illicit drug use. Br. J. Addict. 85, 279-291 (1990).
7. Mello, N. K., Lukas, S. E. & Mendelson, J. H. Buprenorphine effects on cigarette smoking. Psychopharmacology (Berl) 86, 417-425 (1985).
8. Story, J. & Stark, M. J. Treating cigarette smoking in methadone maintenance clients. J. Psychoactive Drugs 23, 203-215 (1991).
9. Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L. et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608-9613 (1998).
10. Zhang, L., Kendler, K. S. & Chen, X. The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav. Brain Funct. 2, 28 (2006).
11. Ray, R., Ruparel, K., Newberg, A., Wileyto, E. P., Loughead, J. W., Divgi, C. et al. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc. Natl Acad. Sci. USA 108, 9268-9273 (2011).
12. Hardin, J., He, Y., Javitz, H. S., Wessel, J., Krasnow, R. E., Tildesley, E. et al. Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. Cancer Epidemiol. Biomarkers Prev. 18, 3399-3406 (2009).
13. Perkins, K. A., Lerman, C., Grottenthaler, A., Ciccocioppo, M. M., Milanak, M., Conklin, C. A. et al. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav. Pharmacol. 19, 641-649 (2008).
14. Crystal, H. A., Hamon, S., Randesi, M., Cook, J., Anastos, K., Lazar, J. et al. A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict. Biol. 17, 181-191 (2012).
15. Ray, R., Jepson, C., Patterson, F., Strasser, A., Rukstalis, M., Perkins, K. et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188, 355-363 (2006).
16. Li, L., Liu, Y., Zhang, Y., Beveridge, T. J. & Zhou, W. Temporal changes of smoking status and motivation among Chinese heroin-dependent, methadone-maintained smokers. Addict. Behav. 35, 861-865 (2010).
17. Benowitz, N. L., Jacob, III P., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J. et al. Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 4, 149-159 (2002).
18. Hecht, S. S., Hochalter, J. B., Villalta, P. W. & Murphy, S. E. 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc. Natl Acad. Sci. USA 97, 12493-12497 (2000).
19. Kreek, M. J. & Koob, G. F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51, 23-47 (1998).
20. Vaccarino, A. L. & Kastin, A. J. Endogenous opiates: 1999. Peptides 21, 1975-2034 (2000).
21. Mague, S. D. & Blendy, J. A. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 108, 172-182 (2010).
22. Berrendero, F., Kieffer, B. L. & Maldonado, R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 22, 10935-10940 (2002).
23. Trigo, J. M., Martin-Garcia, E., Berrendero, F., Robledo, P. & Maldonado, R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 108, 183-194 (2010).
24. Walters, C. L., Cleck, J. N., Kuo, Y. C. & Blendy, J. A. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46, 933-943 (2005).
25. Xue, Y. & Domino, E. F. Tobacco/nicotine and endogenous brain opioids. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1131-1138 (2008).
26. Boyadjieva, N. I. & Sarkar, D. K. The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci. 61, PL59-PL66 (1997).
27. Davenport, K. E., Houdi, A. A. & Van Loon, G. R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113, 40-46 (1990).
28. Contet, C., Kieffer, B. L. & Befort, K. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14, 370-378 (2004).
29. Le Merrer, J., Becker, J. A., Befort, K. & Kieffer, B. L. Reward processing by the opioid system in the brain. Physiol. Rev. 89, 1379-1412 (2009).
30. Deb, I., Chakraborty, J., Gangopadhyay, P. K., Choudhury, S. R. & Das, S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 112, 486-496 (2010).
31. Fillingim, R. B., Kaplan, L., Staud, R., Ness, T. J., Glover, T. L., Campbell, C. M. et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J. Pain 6, 159-167 (2005).
32. Oertel, B. G., Kettner, M., Scholich, K., Renne, C., Roskam, B., Geisslinger, G. et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 284, 6530-6535 (2009).
33. Way, B. M., Taylor, S. E. & Eisenberger, N. I. Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc. Natl Acad. Sci. USA 106, 15079-15084 (2009).
34. Nikolov, M. A., Beltcheva, O., Galabova, A., Ljubenova, A., Jankova, E., Gergov, G. et al. No evidence of association between 118A4G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. Drug Alcohol Depend. 117, 62-65 (2011).
35. Wang, S. C., Tsou, H. H., Chen, C. H., Chen, Y. T., Ho, I. K., Hsiao, C. F. et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur. Neuropsychopharmacol. 22, 695-703 (2012).
36. Munafo, M. R., Elliot, K. M., Murphy, M. F., Walton, R. T. & Johnstone, E. C. Association of the mu-opioid receptor gene with smoking cessation. Pharmacoge-nomics J. 7, 353-361 (2007).
37. Marsden, J., Farrell, M., Bradbury, C., Dale-Perera, A., Eastwood, B., Roxburgh, M. et al. Development of the Treatment Outcomes Profile. Addiction 103, 1450-1460 (2008).
38. Wesson, D. R. & Ling, W. The clinical opiate withdrawal scale (COWS). J. Psychoactive Drugs 35, 253-259 (2003).
39. Guy, W. ECDEU Assessment Manual for Psychopharmacology. Revised edn (U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacol-ogy Research Branch, Division of Extramural Research Programs, Rockville, MD, USA, 1976).
40. Shi, J., Hui, L., Xu, Y., Wang, F., Huang, W. & Hu, G. Sequence variations in the mu opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum. Mutat. 19, 459-460 (2002).
41. Hayashida, M., Nagashima, M., Satoh, Y., Katoh, R., Tagami, M., Ide, S. et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9, 1605-1616 (2008).
42. Compton, P., Geschwind, D. H. & Alarcon, M. Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121B, 76-82 (2003).
43. Yuan, H., Chiou, J., Tseng, W., Liu, C., Liu, C., Lin, Y. et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 34, W635-W641 (2006).
44. Rodi, C., Darnhofer-Patel, B., Stanssens, P., Zabeau, M. & van den Boom, D. A strategy for the rapid discovery of disease markers using the MassARRAY system. Biotechniques 32, S62-S69 (2002).
45. Tost, J. & Gut, I. G. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 38, 335-350 (2005).
46. Storey, J. D. The positive false discovery rate: a bayesian interpretation and the q-Value. Ann. Stat. 31, 2013-2035 (2003).
47. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
48. Wang, S. C., Ho, I. K., Wu, S. L., Liu, S. C., Kuo, H. W., Lin, K. M. et al. Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. Biomed. Chromatogr. 24, 782-788 (2010).
49. Levran, O., Awolesi, O., Linzy, S., Adelson, M. & Kreek, M. J. Haplotype block structure of the genomic region of the mu opioid receptor gene. J. Hum. Genet. 56, 147-155 (2011).
50. Fonseca, F., de la Torre, R., Diaz, L., Pastor, A., Cuyas, E., Pizarro, N. et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 6, e19527 (2011).
51. Wielkoszynski, T., Tyrpien, K. & Szumska, M. The enzyme-linked immunosorbent assay (ELISA) method for nicotine metabolites determination in biological fluids. J. Pharm. Biomed. Anal. 49, 1256-1260 (2009).
52. Elkader, A. K., Brands, B., Selby, P. & Sproule, B. A. Methadone-nicotine interactions in methadone maintenance treatment patients. J. Clin. Psychopharmacol. 29, 231-238 (2009).
53. Gelernter, J., Kranzler, H. & Cubells, J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcoholand drug-dependent subjects. Mol. Psychiatry 4, 476-483 (1999).
54. Bergen, A. W., Kokoszka, J., Peterson, R., Long, J. C., Virkkunen, M., Linnoila, M. et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 2, 490-494 (1997).
55. Tan, E. C., Tan, C. H., Karupathivan, U. & Yap, E. P. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 14, 569-572 (2003).
56. Harte, C. B. & Meston, C. M. Acute effects of nicotine on physiological and subjective sexual arousal in nonsmoking men: a randomized, double-blind, placebo-controlled trial. J. Sex. Med. 5, 110-121 (2008).
57. Hanbury, R., Cohen, M. & Stimmel, B. Adequacy of sexual performance in men maintained on methadone. Am. J. Drug Alcohol Abuse 4, 13-20 (1977).
58. Sharkey, K. M., Kurth, M. E., Anderson, B. J., Corso, R. P., Millman, R. P. & Stein, M. D. Assessing sleep in opioid dependence: a comparison of subjective ratings, sleep diaries, and home polysomnography in methadone maintenance patients. Drug Alcohol Depend. 113, 245-248 (2011).
59. Kurth, M. E., Sharkey, K. M., Millman, R. P., Corso, R. P. & Stein, M. D. Insomnia among methadone-maintained individuals: the feasibility of collecting home polysom-nographic recordings. J. Addict. Dis. 28, 219-225 (2009).
60. Holmen, T. L., Barrett-Connor, E., Holmen, J. & Bjermer, L. Health problems in teenage daily smokers versus nonsmokers, Norway, 1995-1997: the Nord-Trondelag Health Study. Am. J. Epidemiol. 151, 148-155 (2000).
61. Patten, C. A., Choi, W. S., Gillin, J. C. & Pierce, J. P. Depressive symptoms and cigarette smoking predict development and persistence of sleep problems in US adolescents. Pediatrics 106, E23 (2000).
62. Phillips, B. A. & Danner, F. J. Cigarette smoking and sleep disturbance. Arch. Intern. Med. 155, 734-737 (1995).
63. Wetter, D. W. & Young, T. B. The relation between cigarette smoking and sleep disturbance. Prev. Med. 23, 328-334 (1994).
64. Zhang, L., Same, J., Caffo, B. & Punjabi, N. M. Cigarette smoking and nocturnal sleep architecture. Am. J. Epidemiol. 164, 529-537 (2006).
65. Berkman, E. T., Falk, E. B. & Lieberman, M. D. In the trenches of real-world self-control: neural correlates of breaking the link between craving and smoking. Psychol. Sci. 22, 498-506 (2011).
66. Hartwell, K. J., Johnson, K. A., Li, X., Myrick, H., Lematty, T., George, M. S. et al. Neural correlates of craving and resisting craving for tobacco in nicotine dependent smokers. Addict. Biol. 16, 654-666 (2011).
67. Zubieta, J. K., Heitzeg, M. M., Xu, Y., Koeppe, R. A., Ni, L., Guthrie, S. et al. Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. Am. J. Psychiatry 162, 567-577 (2005).